Early and comprehensive biomarker testing in NSCLC is of critical importance as it is associated with improved long-term survival and access to targeted therapies that can dramatically alter the disease course. However, real world assessments in community oncology practices demonstrate that comprehensive NGS-based testing, including evaluation for ERBB2 (HER2) alterations, remains inconsistent and is frequently delayed or omitted, and many clinicians still begin systemic therapy before biomarker test results are available. Significant operational barriers, including inadequate tissue procurement workflows, lack of formal test tracking processes, limited multidisciplinary collaboration, and long turnaround times from outside laboratories compound these gaps, especially in community settings where staffing and infrastructure are constrained. To improve NSCLC biomarker testing and treatment selection, knowledge-based education is only the first step; teams also require practical, system focused support to redesign workflows, standardize testing protocols, and reliably act on molecular testing results. This scalable digital QI program is designed to help community practices close these gaps in the care of patients with advanced/metastatic NSCLC by offering an easy to implement, data driven framework that integrates training, process improvement, and multidisciplinary coordination and can be adapted to practices of all sizes.